1 MCQs in Medicine for NEET PG
A 24-year-old Indian patient with cystic fibrosis homozygous for F508del CFTR mutation presents with progressive dyspnea and recurrent pulmonary exacerbations. He is initiated on elexacaftor-tezacaftor-ivacaftor (ETI) triple therapy. Spirometry is repeated at 4 weeks. The flow-volume loop marked **B** in the diagram shows a curve approaching the predicted normal envelope with reduced scooping compared to his baseline. Which of the following best explains the mechanism underlying this spirometric improvement?
Ready to test yourself?
Test your Medicine knowledge with AI-powered MCQs and detailed explanations — no signup required to try.
Sign up free and practice all 1 Cystic Fibrosis CFTR Modulator Response MCQs with AI-powered explanations tailored to your performance.
Create Free Account